ACD

Advance Cell Diagnostics - a Bio-Techne brand, based in Silicon Valley, ACD's products and pharma assay services are based on its proprietary RNAscope™ technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope and BaseScope™ consisting of assay reagent kits and 15,000+ off-the-shelf probes in addition to a Pharma Assay Services business which allow customers to run assays for their unique targets rapidly. Since its first launch in 2011, the technology boasts 1200+ citations, a new publication each day now, for single, duplex and multiplex RNA analysis. ACD's products and services are based on its proprietary RNAscopeTechnology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development